TearLab Corporation (NASDAQ:TEAR) has been assigned a $4.00 price target by investment analysts at HC Wainwright in a research report issued to clients and investors on Tuesday. The firm currently has a “buy” rating on the medical research company’s stock. HC Wainwright’s target price points to a potential upside of 138.51% from the stock’s previous close.

Other research analysts also recently issued research reports about the company. Rodman & Renshaw lowered their price target on TearLab Corporation from $12.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, May 16th. Zacks Investment Research upgraded TearLab Corporation from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a report on Thursday, May 11th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. TearLab Corporation has an average rating of “Buy” and a consensus price target of $5.05.

TearLab Corporation (TEAR) traded down 22.7143% on Tuesday, reaching $1.6771. The company’s stock had a trading volume of 639,035 shares. The firm has a 50-day moving average price of $2.10 and a 200 day moving average price of $2.90. TearLab Corporation has a 52-week low of $1.55 and a 52-week high of $8.20. The firm’s market capitalization is $9.62 million.

TearLab Corporation (NASDAQ:TEAR) last issued its quarterly earnings results on Monday, August 14th. The medical research company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. The business had revenue of $7 million for the quarter, compared to analysts’ expectations of $6.86 million. During the same quarter in the prior year, the firm posted ($0.08) EPS. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. Equities analysts anticipate that TearLab Corporation will post ($2.82) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/08/15/hc-wainwright-analysts-give-tearlab-corporation-tear-a-4-00-price-target.html.

About TearLab Corporation

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.

Receive News & Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related companies with MarketBeat.com's FREE daily email newsletter.